New MASH drug OPK-88006 enters early safety testing
NCT ID NCT07512427
First seen Apr 15, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug called OPK-88006 in 30 people—first in healthy volunteers, then in those with MASH (a liver condition). The goal is to see if the drug is safe, how the body processes it, and whether it affects weight, liver fat, and other health markers. No treatment benefits are promised at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.